The company aims to position its platform as a validation tool for CRISPR-based therapeutics, while continuing to grow in the oncology space.
In a set of new studies, members of an international team mapped gene variation, expression, and regulatory interactions in developing and adult human brains.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
The startup plans to use the funds to scale its single-cell DNA analysis technology for blood-based cancer research and expand into CRISPR applications.
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Using data for almost 10,900 Latino individuals with diverse ancestry, investigators identified distinct patterns for risky or protective APOE variants.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.
The companies have agreed to offer OnRamp Bioinformatics' genomic data analysis platform with Active Motif's epigenetics research kits.
The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.
ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
With the recent introduction of its Reveal platform, the company behind the 1000 Genomes Project browser wants to unlock the potential of the UK Biobank dataset.
The companies will work together to identify the genetic mutations that cause the rare genetic lysosomal storage disorder alpha mannosidosis.
Using data for nearly 45,000 epilepsy cases and controls, researchers identified loci contributing to focal epilepsy, genetic generalized epilepsy, or unclassified epilepsy.
The company said it will sell off the businesses in order to focus on in vitro diagnostic product development and its diagnostic reagent units.
Research continues to show that it is possible to detect genetic signs of cancer in a blood sample without the need to measure specific oncogenic mutations.
Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.
The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.
UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.